Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Teneligliptin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 known ✓ | P27487 | 20/20 | 1.00 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 1.00 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 1.00 |
| ▸ | PTGS2 | P35354 | 1/20 | 1.00 |
| ▸ | HRH1 | P35367 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Teneligliptin SCHEMBL17270067 | 1.00 | DPP4 (1.00) | DPP4DPP8DPP9PTGS2HRH1 | |
| Teneligliptin SCHEMBL254082 | 1.00 | DPP4 (1.00) | DPP4DPP8DPP9PTGS2HRH1 | |
| Teneligliptin SCHEMBL17270087 | 1.00 | DPP4 (1.00) | DPP4DPP8DPP9PTGS2HRH1 | |
| Teneligliptin SCHEMBL16451097 | 1.00 | DPP4 (1.00) | DPP4DPP8DPP9PTGS2HRH1 | |
| Teneligliptin SCHEMBL2711577 | 0.99 | DPP4 (0.98) | DPP4DPP8DPP9PTGS2HRH1 | |
| Teneligliptin SCHEMBL2142591 | 0.99 | DPP4 (0.98) | DPP4DPP8DPP9PTGS2HRH1 | |
| Teneligliptin SCHEMBL14634647 | 0.99 | DPP4 (0.98) | DPP4DPP8DPP9PTGS2HRH1 | |
| Teneligliptin SCHEMBL17065851 | 0.99 | DPP4 (0.98) | DPP4DPP8DPP9PTGS2HRH1 | |
| Teneligliptin SCHEMBL17065852 | 0.99 | DPP4 (0.98) | DPP4DPP8DPP9PTGS2HRH1 | |
| Teneligliptin SCHEMBL17065854 | 0.98 | DPP4 (1.00) | DPP4DPP8DPP9PTGS2HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1623 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4735023-A2 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE | Piton Therapeutics, Inc. (US) | 2026-05-06 | — | — | EP | claimed |
| US-12599564-B2 | Antidiabetic pharmaceutical compositions | Elite Pharmaceutical Solution Inc. (US) | 2026-04-14 | — | — | US | claimed |
| EP-4694979-A2 | COMPOUNDS FOR UPREGULATING UTROPHIN LEVELS IN MUSCLE CELLS AND METHOD OF APPLICATION THEREOF | Peptris Technologies Private Limited (IN) | 2026-02-18 | — | — | EP | claimed |
| EP-4686474-A1 | DPP-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF AUTOIMMUNE LIVER DISEASES | Delta 4 GmbH (AT) | 2026-02-04 | — | — | EP | claimed |
| EP-4684799-A2 | ANTIBODIES THAT DISRUPT THE INTERACTION OF GAL3 AND INSULIN RECEPTOR OR INTEGRINS AND METHODS OF USE THEREOF | TrueBinding, Inc. (US) | 2026-01-28 | — | — | EP | claimed |
| US-20250325536-A1 | THERAPEUTIC USES OF GLP1R AGONISTS | VTV THERAPEUTICS LLC (US) | 2025-10-23 | — | — | US | claimed |
| US-20250312456-A1 | TREATMENT FOR DIABETES IN PATIENTS INAPPROPRIATE FOR METFORMIN THERAPY | BOEHRINGER INGELHEIM INT (DE) | 2025-10-09 | — | — | US | claimed |
| EP-4596044-A2 | COMBINATION THERAPY OF GPR119 AGONISTS AND DPP-4 INHIBITORS | Mankind Pharma Ltd. (IN) | 2025-08-06 | — | — | EP | claimed |
| EP-4566590-A1 | TASTE-MASKING MICROSPHERE, PREPARATION PROCESS THEREFOR, AND USE THEREOF | Harbin Kanon Pharmaceutical Co., Ltd (CN) | 2025-06-11 | — | — | EP | claimed |
| WO-2025104674-A1 | COMBINATION THERAPY FOR TREATING NEURODEGENERATIVE DISORDERS | ARIBIO CO., LTD. (KR) | 2025-05-22 | — | — | WO | claimed |
| WO-2010018217-A2 | ORGANIC COMPOUNDS FOR WOUND HEALING | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-02-18 | — | — | WO | claimed |
| WO-2010015664-A1 | TREATMENT FOR DIABETES IN PATIENTS INAPPROPRIATE FOR METFORMIN THERAPY | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-02-11 | — | — | WO | claimed |
| US-20090216016-A1 | SALT OF PROLINE DERIVATIVE, SOLVATE THEREOF, AND PRODUCTION METHOD THEREOF | MITSUBISHI PHARMA CORPORATION (JP) | 2009-08-27 | — | — | US | claimed |
| US-20090088442-A1 | PROPHYLACTIC/THERAPEUTIC AGENT FOR ABNORMALITIES OF SUGAR/LIPID METABOLISM | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-04-02 | — | — | US | claimed |
| US-20090082256-A1 | CONCOMITANT PHARMACEUTICAL AGENTS AND USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-03-26 | — | — | US | claimed |
| EP-1894567-A1 | CONCOMITANT PHARMACEUTICAL AGENTS AND USE THEREOF | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-03-05 | — | — | EP | claimed |
| EP-1882474-A1 | PROPHYLACTIC/THERAPEUTIC AGENT FOR ABNORMALITIES OF SUGAR/LIPID METABOLISM | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-01-30 | — | — | EP | claimed |
| EP-1854795-A1 | SALT OF PROLINE DERIVATIVE, SOLVATE THEREOF, AND PRODUCTION METHOD THEREOF | MITSUBISHI PHARMA CORPORATION (JP) | 2007-11-14 | — | — | EP | claimed |
| US-20060173056-A1 | Proline derivatives and use thereof as drugs | KITAJIMA HIROSHI | 2006-08-03 | — | — | US | claimed |
| US-7074794-B2 | Proline derivatives and the use thereof as drugs | MITSUBISHI PHARMA CORPORATION (JP) | 2006-07-11 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060173056-A1 | Proline derivatives and use thereof as drugs | DPP4, DPP3, DPP7 | DPP4 1/4885DPP8 6/4885DPP9 5/4885 |
| US-20090082256-A1 | CONCOMITANT PHARMACEUTICAL AGENTS AND USE THEREOF | DPP4, DPP7, LIPC | DPP4 1/4885DPP8 4/4885DPP9 5/4885 |
| US-20250312456-A1 | TREATMENT FOR DIABETES IN PATIENTS INAPPROPRIATE FOR METFORMIN THERAPY | DPP4, DPP3, DPP7 | DPP4 1/4885DPP8 5/4885DPP9 4/4885 |
| US-20090088442-A1 | PROPHYLACTIC/THERAPEUTIC AGENT FOR ABNORMALITIES OF SUGAR/LIPID METABOLISM | UGCG, PNLIP, SLC2A1 | DPP4 558/4885DPP8 949/4885DPP9 1118/4885 |
| US-12599564-B2 | Antidiabetic pharmaceutical compositions | GLP1R, DPP4, SLC5A2 | DPP4 2/4885DPP8 11/4885DPP9 16/4885 |
| US-20090216016-A1 | SALT OF PROLINE DERIVATIVE, SOLVATE THEREOF, AND PRODUCTION METHOD THEREOF | DPP4, DPP3, PEPD | DPP4 1/4885DPP8 6/4885DPP9 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.